

## Asst. Prof. ZEYNEP MELEKOĞLU ELLİK

### Personal Information

**Email:** ellik@ankara.edu.tr

**Web:** <https://avesis.ankara.edu.tr/ellik>

### International Researcher IDs

ORCID: 0000-0001-8290-7965

Publons / Web Of Science ResearcherID: JAO-1030-2023

Yoksis Researcher ID: 145029

### Education Information

Post Doctorate of Medicine, Ankara University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Turkey 2017 - 2021

Expertise In Medicine, Baskent University, Turkey 2012 - 2016

Undergraduate, Ankara University, Tıp Fakültesi, Turkey 2003 - 2009

### Research Areas

Gastroenterology and Hepatology

### Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Assessing hepatic steatosis by magnetic resonance in potential living liver donors**  
Kuru Öz D., Ellik Z., Gürsoy Çoruh A., Adıgüzel M., Gümüşsoy M., Kiremitci S., Kırımker O. E., Gökcan H., Elhan A. H., Balcı D., et al.  
Diagnostic and Interventional Radiology, vol.30, no.6, pp.351-356, 2024 (SCI-Expanded)
- II. **HEPATIC STEATOSIS IS ASSOCIATED WITH HBSAG CLEARANCE IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION**  
BODAKÇI E., KİREMİTÇİ S., DUMAN S., MELEKOĞLU ELLİK Z., Gumussoy M., GÜVENİR S. T., Yılmaz V., ER R. E., Karakaya F., GÖKCAN H., et al.  
HEPATOLOGY, 2024 (SCI-Expanded)
- III. **Changing Trends in the Etiology of Cirrhosis in Türkiye: A Multicenter Nationwide Study**  
Üçbilek E., Yıldırım A. E., Ellik Z., Turan İ., HAKTANIYAN B., Orucu B., DEMİR M., Tozlu M., Yılmaz N., BALABAN H. Y., et al.  
Turkish Journal of Gastroenterology, vol.35, no.10, pp.772-777, 2024 (SCI-Expanded)
- IV. **Liver Stiffness and Steatosis Measurements with iLivTouch and FibroScan: A Comparative Study.**  
Özercan M., Melekoğlu Ellik Z., Parmaksız A., Gümüşsoy M., Duman S., Örmeci N.  
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, vol.35, no.8, pp.634-642, 2024 (SCI-Expanded)
- V. **A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone**  
Duman S., Kuru D., Gumussoy M., KİREMİTÇİ S., GÖKCAN H., Ulas B., Ellik Z., Ozercan M., ER R. E., Karakaya F., et al.  
EUROPEAN RADIOLOGY, vol.34, no.6, pp.3882-3888, 2024 (SCI-Expanded)

- VI. **Determining Subclinical Cardiovascular and Cardiac Diseases in Patients with Non-Alcoholic Fatty Liver Disease**  
Karaođlan B. B., Tulunay C., Uzun Ç., Peker E., Özyüncü N., Ellik Z., Kuru D., Turhan S., Savaş B., Erden A., et al.  
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.34, no.3, pp.242-253, 2023 (SCI-Expanded)
- VII. **Factors associated with the development of extrahepatic malignancy in patients with nonalcoholic fatty liver disease: a single-center longitudinal study**  
Gumussoy M., Koc O., KARATAŞ G., Ozercan M., Ellik Z., DUMAN S., KİREMİTÇİ S., GÖKCAN H., ELHAN A. H., SAVAŞ B., et al.  
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.34, no.11, pp.1172-1177, 2022 (SCI-Expanded)
- VIII. **EFFECT OF PROGNOSTIC NONINVASIVE TESTS ON DISEASE OUTCOME OF ALCOHOL-RELATED LIVER DISEASE**  
Zengin B. A., Gumussoy M., Duman S., Bodakçi E., Güvenir S. T., Ellik Z., Ozercan M., Er R. E., Karakaya M. F., Sumer H., et al.  
HEPATOLOGY, vol.76, 2022 (SCI-Expanded)
- IX. **An imaging-based artificial intelligence model for non-invasive grading of hepatic venous pressure gradient in cirrhotic portal hypertension**  
Yu Q., Huang Y., Li X., Pavlides M., Liu D., Luo H., Ding H., An W., Liu F., Zuo C., et al.  
CELL REPORTS MEDICINE, vol.3, no.3, 2022 (SCI-Expanded)
- X. **Evaluation of Magnetic Resonance Elastography and Transient Elastography for Liver Fibrosis and Steatosis Assessments in the Liver Transplant Setting**  
Ellik Z., İDİLMAN İ. S., Kartal A., Balaban Y., ELHAN A. H., KARÇAALTINCABA M., ÖZKAN H., İDİLMAN R.  
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.33, no.2, pp.153-160, 2022 (SCI-Expanded)
- XI. **Noncontrast-enhanced MRI-based Noninvasive Score for Portal Hypertension (CHESS1802): An International Multicenter Study**  
Liu Y., Tang T., Ormeci N., Huang Y., Wang J., Li X., Li Z., An W., Liu D., Zhang C., et al.  
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, vol.9, no.6, pp.818-827, 2021 (SCI-Expanded)
- XII. **Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study**  
Efe C., Dhanasekaran R., Lammert C., Ebik B., Higuera-de la Tijera F., Aloman C., Caliskan A. R., Peralta M., Gerussi A., Massoumi H., et al.  
HEPATOLOGY, vol.73, no.6, pp.2099-2109, 2021 (SCI-Expanded)
- XIII. **Natural History of Cirrhosis: Changing Trends in Etiology Over the Years**  
İDİLMAN R., Aydoğan M., Oruncu M. B., Kartal A., ELHAN A. H., Ellik Z., Gumussoy M., Er R. E., Ozercan M., DUMAN S., et al.  
DIGESTIVE DISEASES, vol.39, no.4, pp.358-365, 2021 (SCI-Expanded)
- XIV. **Deep Convolutional Neural Network-Aided Detection of Portal Hypertension in Patients With Cirrhosis**  
Liu Y., Ning Z., Ormeci N., An W., Yu Q., Han K., Huang Y., Liu D., Liu F., Li Z., et al.  
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, vol.18, no.13, pp.2998-3012, 2020 (SCI-Expanded)

## Articles Published in Other Journals

- I. **Use of Endoscopic Ultrasound Elastography to Differentiate between Gastrointestinal Stromal Tumor and Leiomyoma Localized in the Upper Gastrointestinal Tract.**  
Erdem R. E., Bektaş M., Ellik Z., Ceyhan K.  
Euroasian journal of hepato-gastroenterology, vol.14, no.1, pp.20-23, 2024 (Peer-Reviewed Journal)
- II. **Changing trends in the etiology of liver transplantation in Türkiye: A multicenter study**  
AKARSU M., Harputluođlu M., AKYILDIZ M., GENÇDAL G., DİNÇER D., ADANIR H., TURAN İ., GÜNŞAR F., KARASU A. Z., GÖKCAN H., et al.  
Hepatology forum, vol.5, no.1, pp.3-6, 2024 (ESCI)

- III. **Inflammatory Patterns of Crohn's Terminal Ileitis**  
SEVİM S., KOVARI B. P., YAVAŞ A., SALMAN F. G., MELEKOĞLU ELLİK Z., SAVAŞ B., ÇETİNKAYA H., TÖRÜNER M., ENSARİ A.  
GASTROENTEROLOGY AND HEPATOLOGY FROM BED TO BENCH, 2023 (Scopus)
- IV. **Comparison of angiotensin converting enzyme inhibitor and/or angiotensin receptor blocker treatments of patients in 3 different patient groups with proteinuria**  
MELEKOĞLU ELLİK Z., SAYIN C. B.  
Turkish Journal of Clinics and Laboratory, vol.14, no.3, 2023 (Peer-Reviewed Journal)
- V. **Muscle hydatid diseases: percutaneous treatment with Örmeci technique**  
Örmeci N., Asiller Ö. Ö., Yağcı C., Örmeci T., Ellik Z., Kalkan Ç., Elhan A. H.  
Journal of Health Sciences and Medicine, vol.5, no.3, pp.732-739, 2022 (Peer-Reviewed Journal)
- VI. **Clinical significance of concomitant extrahepatic autoimmune disease in patients with autoimmune liver disease**  
KARAKAYA M. F., USTA Ş., ÖZTÜRK Y., KALKAN Ç., MELEKOĞLU ELLİK Z., ELHAN A. H., SOYKAN A. İ., İDİLMAN R.  
Hepatology Forum, vol.1, no.2, pp.3-6, 2021 (ESCI)
- VII. **Percutaneous treatment with the Örmeci technique of cystic echinococcosis: experience of single center**  
ÖRMECİ N., ASİLLER Ö. Ö., KALKAN Ç., ELLİK Z., ÇALIŞKAN KARTAL A., ER R. E., ELHAN A. H.  
Gastroenterology Hepatology: Open Access, vol.11, no.6, pp.223-230, 2020 (Peer-Reviewed Journal)
- VIII. **A rare disease that presents with acute severe hepatitis: Kikuchi-Fujimoto disease**  
ÇALIŞKAN KARTAL A., İDİLMAN R., MELEKOĞLU ELLİK Z., SAĞLAM A., CİVRİZ BOZDAĞ S.  
Hepatology forum, vol.1, pp.41-42, 2020 (Scopus)

## Books & Book Chapters

- I. **Gebelikte Gastrointestinal Sistem Hastalıkları**  
MELEKOĞLU ELLİK Z.  
in: Temelden Kliniğe Kadın Genital Sistem, YAKINCI MEHMET CENGİZ, MELEKOĞLU RAUF, VARDI NİGAR, Editor, NOBEL TIP KİTABEVLERİ, İstanbul, pp.406-411, 2024
- II. **Management of Diabetes Mellitus in Liver Cirrhosis**  
MELEKOĞLU ELLİK Z.  
in: CURRENT PERSPECTIVE ON DIABETES MELLITUS IN CLINICAL SCİENCE, Alp Harun, Rağbetli Murat Çetin, Köksoy Hale, Editor, Nobel Tıp Kitapevleri, Ankara, pp.399-412, 2023
- III. **Gebelik ve Diyare**  
MELEKOĞLU ELLİK Z., YILMAZ V.  
in: Gastroenteroloji ve Gebelik, YÜKSEL MAHMUT, YEŞİL BAYRAM, KÖSEOĞLU HASAN TANKUT, PİRİNÇÇİ SAPMAZ FERDANE, ERÜRKER ÖZTÜRK TUBA, HAMAMCI MEVLÜT, Editor, AKADEMİSYEN KİTABEVİ, Ankara, pp.165-170, 2023
- IV. **COVID-19 sürecinde biyobelirteç olarak AST/ALT**  
MELEKOĞLU ELLİK Z.  
in: COVID-19 Sürecinde Biyobelirteçlerin Klinik Pratikte Kullanımı, Kurt Yüksel Meltem, Editor, Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş, Ankara, pp.74-77, 2021
- V. **Obezitenin Tıbbi, Cerrahi ve Endoskopik Tedavisi**  
MELEKOĞLU ELLİK Z.  
in: Yamada Gastroenteroloji El Kitabı, Korkut Esin, Editor, İstanbul Tıp Kitapevi, İstanbul, pp.457-462, 2021
- VI. **Gastrointestinal Vasküler Lezyonlar**  
MELEKOĞLU ELLİK Z.  
in: Yamada Gastroenteroloji El Kitabı, Korkut Esin, Editor, İstanbul Tıp Kitapevi, İstanbul, pp.447-456, 2021
- VII. **Portal Hipertansiyon Medikal Tedavisi**  
MELEKOĞLU ELLİK Z.

in: Portal Hipertansiyon, ÖRMECİ NECATİ, BİLGİÇ SADIK, Editor, Arena Kağıtçılık Matbaacılık, İstanbul, pp.140-149, 2020

VIII. **Endoskopik Submukozal Diseksiyon**

MELEKOĞLU ELLİK Z., BEKTAŞ M.

in: Mide Kanserine Minimal İnvaziv Yaklaşım, Demirci Salim , Ünal Ali Ekrem Ünal, Bayar Sancar, Erşen Ogün Erşen, Mercan Ümit, Editor, Akademisyen Kitabevi Yayınevi, Ankara, pp.81-89, 2020

**Refereed Congress / Symposium Publications in Proceedings**

- I. **De novo malignancies after liver transplantation: multicenter study a preliminary report**  
Danis N., Akarsu M., Harputluoglu M., Yilmaz S., Adanir H., Dincer D., Turan D., Kayhan M. A., Turan I., Gunsar F., et al.  
International Congress of the International-Liver-Transplantation-Society (ILTS), Texas, United States Of America, 1 - 04 May 2024, pp.165-166
- II. **The impact of tumor budding in patients with hepatocellular carcinoma**  
Duran o. f., GÖKCAN H., KİREMİTÇİ S., YILMAZ V., ÇİFTÇİ A., BODAKÇI E., GÜMÜŞSOY M., MELEKOĞLU ELLİK Z., ÖZERCAN A. M., İDİLMAN R.  
EASL congress 2024, 05 June 2024
- III. **Histological and clinical disease progression in patients with metabolic associated steatotic liver disease using paired biopsy**  
ekelik m., TURAN D., GÜMÜŞSOY M., KİREMİTÇİ S., BODAKÇI E., yilmaz v., DUMAN S., MELEKOĞLU ELLİK Z., ER R. E., GÖKCAN H., et al.  
EASL congress 2024, 05 June 2024
- IV. **Assesing Hepatic Steatosis by MRI in potential living liver donors**  
Kuru Öz d., MELEKOĞLU ELLİK Z., GÜRİSOY ÇORUH A., GÜMÜŞSOY M., kırımker o. e., GÖKCAN H., BALCI D., ERDEN A., İDİLMAN R.  
AASLD-TASL hepatology connect meeting 2024, 16 February 2024
- V. **The impact of tumor budding on tumor biology in patients with hepatocellular carcinoma**  
Duran O. F., GÖKCAN H., KİREMİTÇİ S., GÜVENİR S. T., YILMAZ V., BODAKÇI E., GÜMÜŞSOY M., MELEKOĞLU ELLİK Z., ÖZERCAN A. M., DUMAN S., et al.  
AASLD-TASL hepatology connect meeting 2024, 16 February 2024
- VI. **Histological and Clinical disease Progression in Patients with Metabolic Dysfunction associated Steatotic Liver Disease Isinig Paired Biopsy**  
Ekelik M. M., TURAN D., GÜMÜŞSOY M., KİREMİTÇİ S., BODAKÇI E., YILMAZ V., DUMAN S., MELEKOĞLU ELLİK Z., ÖZERCAN A. M., ER R. E., et al.  
AASLD-TASL hepatology connect meeting 2024, 16 February 2024
- VII. **Hepatic steatosis is associated with HbsAg clearnce in patients with chronic hepatitis B infection**  
BODAKÇI E., DUMAN S., KİREMİTÇİ S., MELEKOĞLU ELLİK Z., GÜMÜŞSOY M., ER R. E., KARAKAYA M. F., GÖKCAN H., elhan a., SAVAŞ B., et al.  
AASLD-TASL hepatology connect meeting 2024, 16 February 2024
- VIII. **SAT-519 The impact of tumor budding on tumor biology in patients with hepatocellular carcinoma**  
DURAN O. F., GÖKCAN H., KİREMİTÇİ S., GÜVENİR S. T., YILMAZ V., BODAKÇI E., GÜMÜŞSOY M., MELEKOĞLU ELLİK Z., ÖZERCAN A. M., DUMAN S., et al.  
AASLD-TASL hepatology connect meeting, 16 February 2024
- IX. **Noninvazive fibrosis markers for assesment for liver fibrosis in patients with chronic hepatitis delta**  
KARAKAYA M. F., KURU ÖZ D., Turan D., DUMAN S., MELEKOĞLU ELLİK Z., GÜMÜŞSOY M., GÜVENİR S. T., YILMAZ V., GÖKCAN H., İDİLMAN R.  
AASLD 2023 congress, United States Of America, 10 November 2023
- X. **development of Metabolic Disorders in Transplant Recepients**  
Erdemir G., GÖKCAN H., Gürsoy Çoruh A., GÜLPINAR B., MELEKOĞLU ELLİK Z., GÜMÜŞSOY M., DUMAN S., BODAKÇI

E., İDİLMAN R.

EASL Congress 21-24 June 2023, Austria, 21 - 24 June 2023, vol.78, pp.477-478

- XI. **A Combination Of Non-Invasive Tests In Detection Of NAFLD-Related Advanced Fibrosis Is Not Superior To MRE Alone**  
Duman S., Gümüşsoy M., Kuru D., Kiremitci S., Gökcan H., Bodakçı E., Melekoğlu Z., Ulaş B., Elhan A. H., Savaş B., et al.  
39. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber, Bochum, Germany, 27 - 28 January 2023, vol.61, pp.30
- XII. **Alkol Dışı Yağlı Karaciğer Hastalığı Doğal Seyri: Ardışık İkili Karaciğer Biyopsilerinin Karşılaştırılması**  
GÜMÜŞSOY M., TURAN D., EKELİK M., KİREMİTÇİ S., BODAKÇI E., DUMAN S., MELEKOĞLU ELLİK Z., GÜVENİR S. T., ER R. E., KARAKAYA M. F., et al.  
39. ULUSAL GASTROENTEROLOJİ HAFTASI, Antalya, Turkey, 22 November 2022
- XIII. **Alkole Bağlı Karaciğer Hastalığında Prognostik Non-İnvasif Testlerin Hastalık Sonucunu Öngörmede Etkinliği**  
ZENGİN B. A., GÜMÜŞSOY M., DUMAN S., BODAKÇI E., GÜVENİR S. T., MELEKOĞLU ELLİK Z., ÖZERCAN A. M., ER R. E., KARAKAYA M. F., GÖKCAN H., et al.  
39. ULUSAL GASTROENTEROLOJİ HAFTASI, Antalya, Turkey, 22 November 2022
- XIV. **Natural disease Outcome in patients with NAFLD: A study with paired liver biopsy**  
GÜMÜŞSOY M., Turan Gökçe D., KİREMİTÇİ S., BODAKÇI E., DUMAN S., MELEKOĞLU ELLİK Z., GÜVENİR S. T., ER R. E., KARAKAYA M. F., GÖKCAN H., et al.  
aasld 2022, 04 November 2022
- XV. **Effect of prognostic noninvasive tests on disease outcome of alcohol related liver disease**  
zengin a., GÜMÜŞSOY M., DUMAN S., BODAKÇI E., GÜVENİR S. T., MELEKOĞLU ELLİK Z., ÖZERCAN A. M., ER R. E., KARAKAYA M. F., İDİLMAN R.  
aasld 2022, 04 November 2022
- XVI. **Real Life Efficacy and tolerability of Tenofovir alafenamide fumarate in patients with hepatitis B virus related cirrhosis**  
YAPALI S., GÖKCAN H., DURAK S., MELEKOĞLU ELLİK Z., ADANIR H., GÜNDÜZ F. F., ÖZDİL K., DİNÇER D., İDİLMAN R.  
international Liver congress ILC 2022 (EASL), 22 - 26 June 2022
- XVII. **Real Life Efficacy and tolerability of Tenofovir alafenamide fumarate in liver transplant recipients: a multicenter study**  
GÖKCAN H., YAPALI S., MELEKOĞLU ELLİK Z., GÖKÇEN P., ADANIR H., DURAK S., ARI D., GÜZELBULUT F., EKMEK N., YILDIRIM A. E., et al.  
international Liver congress ILC 2022 (EASL), 22 - 26 June 2022
- XVIII. **Trends and causes of etiology in adult liver transplant patients: multicenter study**  
AKARSU M., Harputluoğlu M., YILMAZ S., GENÇDAL G., AKYILDIZ M., DİNÇER D., ADANIR H., TURAN İ., GÜNŞAR F., KARASU A. Z., et al.  
international Liver congress ILC 2022 (EASL), 22 - 26 June 2022
- XIX. **Effectiveness of MRI methods in the assesment of hepatic steatosis in living liver donors**  
KURU ÖZ D., MELEKOĞLU ELLİK Z., GÜRSOY ÇORUH A., GÜMÜŞSOY M., DUMANLI S., ER R. E., BALCI D., GÖKCAN H., İDİLMAN R., ERDEN A.  
international Liver congress ILC 2022 (EASL), 22 June 2022
- XX. **Preliminary Results of The effectiveness and safety of Tenofovir alafenamide Fumarate Prophylaxis in HBV individuals, who received Chemo/Immunsuppression therapy**  
GÜNDÜZ F. F., DURAK S., ÜNSAL Y., DEMİR M., MELEKOĞLU ELLİK Z., YILDIRIM A. E., ADANIR H., DEMİRTAŞ C. Ö., BALABAN H. Y., ÖZER ETİK D., et al.  
international Liver congress ILC 2022 (EASL), 22 June 2022
- XXI. **Real life efficacy and tolerability of Tenofovir alafenamide fumarate in liver transplant recipients: a multicenter study (SAT416)**  
GÖKCAN H., YAPALI S., HARPUTLUOĞLU M. M. M., MELEKOĞLU ELLİK Z., GÖKÇEN P., ADANIR H., COŞAR A. M.,

DURAK S., ARI D., MEHDİYEV S., et al.

EASL The International Liver Congress, London, Canada, 26 June 2022

- XXII. **Real life efficacy and tolerability of Tenofovir Alafenamide Fumarate in patients with hepatitis-B virus-related cirrhosis (SAT421)**  
YAPALI S., GÖKCAN H., DURAK S., MELEKOĞLU ELLİK Z., GÜZELBULUT F., VATANSEVER S., ARI D., MEHDİYEV S., ADANIR H., KOÇ E. S., et al.  
EASL The International Liver Congress, London, Canada, 22 June 2022
- XXIII. **Real Life Efficacy and tolerability of Tenofovir alafenamide fumarate in liver transplant recipients: A multicenter study**  
YAPALI S., GÖKCAN H., MELEKOĞLU ELLİK Z., GÖKÇEN P., ADANIR H., DURAK S., ARI D., GÜZELBULUT F., EKME N., ÖZER ETİK D., et al.  
ILTS 2022, 04 May 2022
- XXIV. **Real life efficacy and tolerability of tenofovir alafenamide fumarate in liver transplant recipients: A multicenter study**  
YAPALI S., GÖKCAN H., harputluoğlu M., MELEKOĞLU ELLİK Z., GÖKÇEN P., ADANIR H., ARI D., mehdiyev s., BİLGİÇ Y., GÜZELBULUT F., et al.  
AASLD TAsL Digital Hepatology Meeting, Turkey, 14 - 15 January 2022, vol.3, pp.4
- XXV. **Biliary complications and management in liver transplant recipients with duct to duct anastomosis: A single center experience**  
KARAKAYA M. F., ÇINAR K., ER R. E., KIRIMKER E. O., BALCI D., ÖZERCAN A. M., GÜMÜŞSOY M., MELEKOĞLU ELLİK Z., DOĞANAY ERDOĞAN B., GÖKCAN H., et al.  
AASLD-TAsL Digital Hepatology Meeting, 14 January 2022
- XXVI. **Real Life Efficacy and tolerability of Tenofovir alafenamide fumarate in patients with hepatitis B virus related cirrhosis**  
YAPALI S., GÖKCAN H., DURAK S., MELEKOĞLU ELLİK Z., VATANSEVER S., ADANIR H., GÜNDÜZ F. F., ÖZDİL K., DİNÇER D., İDİLMAN R.  
AASLD-TAsL digital Hepatology Connect, 14 April 2022
- XXVII. **Trends and changes of etiology in adult liver transplant patients: multicenter study**  
AKARSU M., Harputluoğlu M., YILMAZ S., AKYILDIZ M., GENÇDAL G., polat k. y., DİNÇER D., ADANIR H., TURAN İ., GÜNŞAR F., et al.  
AASLD-TAsL digital Hepatology Connect, 14 January 2022
- XXVIII. **Biliary Complications and Management in Liver Transplant Patients with Duct to Duct Anastomosis: Single Center Experience**  
KARAKAYA M. F., ÇINAR K., ER R. E., KIRIMKER E. O., BALCI D., ÖZERCAN A. M., GÜMÜŞSOY M., MELEKOĞLU ELLİK Z., ERDOĞAN AKTÜRK B., GÖKCAN H., et al.  
AASLD-TAsL digital Hepatology Connect, 14 January 2022
- XXIX. **Kemoterapi ve İmmünoşüpresif Tedavi Alan Hastalarda Hepatit B Reaktivasyon Profilaksisinde Tenofovir Alafenamid Fumaratın Etkinliği ve Güvenliği: Çok Merkezli-Gözlemsel Çalışmanın İlk Sonuçları**  
GÜNDÜZ F., DURAK S., ÜNSAL Y., DEMİR M., MELEKOĞLU ELLİK Z., YILDIRIM E., MEHDİYEV S., ADANIR H., ÜÇBİLEK E., BALABAN H. Y., et al.  
38. Ulusal Gastroenteroloji Haftası 16-21 Kasım 2021, Antalya, 16 November 2021
- XXX. **Tenofovir Alafenamid Fumaratın Hepatit B virüsü ile İlişkili Sirozlu Hastalar ve Post-transplant Hastalarda Gerçek Yaşam Etkinliği ve Tolere Edilebilirliğinin Ön Sonuçları**  
YAPALI S., GÖKCAN H., HARPUTLUOĞLU M., MELEKOĞLU ELLİK Z., AKARSU M., DURAK S., GÖKÇEN P., ADANIR H., ARI D., MEHDİYEV S., et al.  
38. Ulusal Gastroenteroloji Haftası 16-21 Kasım 2021, Antalya, 16 November 2021
- XXXI. **'Duct to Duct Anastomozlu' Karaciğer Transplantasyon Hastalarında Biliyer Komplikasyonlar ve Yönetimi: Tek Merkez Deneyimi**  
KARAKAYA M. F., ÇINAR K., ER R. E., KIRIMKER E. O., BALCI D., ÖZERCAN A. M., GÜMÜŞSOY M., MELEKOĞLU ELLİK Z., DOĞANAY ERDOĞAN B., DUMLUPINAR E., et al.

38. ULUSAL GASTROENTEROLOJİ HAFTASI, Antalya, Turkey, 16 November 2021

- XXXII. **Real life Efficacy and Tolerability of Tenofovir alafenamide fumarate in patients with hepatitis B virus related cirrhosis and liver transplant recipients: a preliminary result**  
YAPALI S., GÖKCAN H., Harputluoğlu M., MELEKOĞLU ELLİK Z., AKARSU M., ADANIR H., ARI D., VATANSEVER S., GÜZELBULUT F., ÖZER ETİK D., et al.  
AASLD 2021 congress, 05 November 2021
- XXXIII. **Real Life Efficacy and Tolerability of Tenofovir Alafenamide Fumarate in Patients with Hepatitis B Virus-related Cirrhosis and Liver Transplant Recipients. A-Preliminary Result (798)**  
YAPALI S., GÖKCAN H., HARPUTLUOĞLU M. M. M., MELEKOĞLU ELLİK Z., AKARSU M., DURAK S., GÖKÇEN P., ADANIR H., ARI D., MEHDİYEV S., et al.  
AASLD the Liver Meeting Digital Experience, United States Of America, 12 November 2021, vol.74, pp.490
- XXXIV. **association. between non-alcoholic fatty liver disease and extrahepatic malignancy**  
GÜMÜŞSOY M., İDİLMAN R., GÖKCAN H., BODAKÇI E., ÖZERCAN M., ER R. E., MELEKOĞLU ELLİK Z.  
EASL congress 2021, 23 June 2021
- XXXV. **Outcome of COVID-19 in Patients with Autoimmune Hepatitis: An International Multi-Centre Study**  
EFE C., BATIBAY E., DHANASEKARAN R., LAMMERT C., ALOMAN C., MASSOUMI H., M. CATANA A., KHAKOO N., FRAGER S., PÜRNAK T., et al.  
17. Ulusal Hepato-Gastroenteroloji Kongresi & Middle East & North Africa EUS Club 4th MENA EUS & ERCP Workshop, 17 - 19 June 2021
- XXXVI. **Kemoterapi ve İmmünsüpresif Tedavi Alan Hastalarda Hepatit B Reaktivasyon Profilaksisinde Tenofovir Alafenamide Fumarat'ın Etkinliği ve Güvenirliği: Çok Merkezli-Gözlemsel Çalışmanın İlk Sonuçları**  
GÜNDÜZ F., ÜNSAL Y., MELEKOĞLU ELLİK Z., MEHDİYEV S., YILDIRIM E., ADANIR H., YÖRÜK G., SÜRME S., KOÇ E. S., BALABAN H. Y., et al.  
13. ULUSAL HEPATOLOJİ KONGRESİ ULUSLARARASI KATILIMLI, 28 - 30 May 2021
- XXXVII. **EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE IN CHRONIC HEPATITIS B PATIENTS WITH CHRONIC HEMODIALYSIS AND KIDNEY TRANSPLANTATION- REALITY STUDY**  
ADANIR H., MELEKOĞLU ELLİK Z., YILDIRIM A. E., GÜNDÜZ F. F., GÖKCAN H., YARAŞ S., AKDOĞAN KAYHAN M., BALABAN H. Y., ALKIM H., YAPALI S., et al.  
AASLD-TASL Digital Hepatology Connect Meeting, 2021, 15 September 2021
- XXXVIII. **The analysis of liver transplant patients with COVID-19 infection: a national cohort**  
KABAÇAM G., TURAN İ., KIYICI M., MELEKOĞLU ELLİK Z., DOLU S., DAYANGAÇ M., ARI D., TURAN GÖKÇE D., YILDIRIM A. E., GENÇDAL G., et al.  
AASLD-TASL digital Hepatology Connect, İstanbul, Turkey, 15 - 16 January 2021, vol.2, pp.24-25
- XXXIX. **Non-alcoholic fatty liver disease and extrahepatic malignancy**  
Gümüşsoy M., Turan Gökçe D., Ulaş B. B., Koç Ö., Karataş G., Bodakçı E., Özercan M., DUMAN S., MELEKOĞLU ELLİK Z., KARAKAYA M. F., et al.  
AASLD-TASL digital Hepatology Connect, 15 January 2021
- XL. **Diagnostic accuracy of liver stiffness measurement by fibroscan in liver transplant recipients**  
MELEKOĞLU ELLİK Z., ÇALIŞKAN A., DUMAN S., GÜMÜŞSOY M., ÖZERCAN A. M., ER R. E., ELHAN A. H., İDİLMAN R.  
EASL: The Digital International Liver Congress, 27 - 29 August 2020, vol.73, pp.528
- XLI. **Deep learning of CT/MR images for non-invasive detection of clinically significant portal hypertension in patients with cirrhosis: results from two prospective multicenter cohorts**  
XIAOLONG Q., ZHENYUAN N., YU Q., LIU Y., HAN K., HUANG Y., HAN W., LIU D., LIU F., LI Z., et al.  
HEPATOLOGY Annual Meeting of the American Association for the Study of the Liver Diseases AASLD-liver meeting, BOSTON, United States Of America, 8 - 12 November 2019, vol.70, pp.99-100
- XLII. **NOVEL QUANTIFICATION OF LIVER SURFACE NODULARITY BASED ON NON-CONTRAST-ENHANCED MR IMAGES FOR IDENTIFICATION OF CLINICALLY SIGNIFICANT PORTAL HYPERTENSION: A PROSPECTIVE, MULTICENTER STUDY**  
Liu Y., Tang T., Huang Y., Ji J., Yu Q., Meng X., Liu J., Liu D., Liu C., Liu C., et al.  
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting,

Massachusetts, United States Of America, 8 - 12 November 2019, vol.70

- XLIII. **DEEP LEARNING OF CT/MR IMAGES FOR NON-INVASIVE DETECTION OF CLINICALLY SIGNIFICANT PORTAL HYPERTENSION IN PATIENTS WITH CIRRHOSIS: RESULTS FROM TWO PROSPECTIVE, MULTICENTER COHORTS**  
Qi X, Ning Z, Yu Q, Liu Y, Han K, Huang Y, An W, Liu D, Liu F, Li Z, et al.  
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, United States Of America, 8 - 12 November 2019, vol.70
- XLIV. **Serum or urinary neopterin which is the best for evaluate disease activity in inflammatory bowel disease?**  
ÇETİNKAYA H., MELEKOĞLU ELLİK Z., KENARLI K., DUMAN S., EVREN E., KARAHAN Z. C., TÖRÜNER M.  
Proceedings of the World Congress of Gastroenterology, İstanbul, Turkey, 21 - 24 September 2019, vol.30, pp.810
- XLV. **Comparison of the efficacy of short term and long term nucleos(t)ide analog treatment in chronic delta hepatitis**  
YURTAYDIN S. C., KESKİN O., KARAKAYA M. F., YILMAZ Y., ÇALIŞKAN KARTAL A., MELEKOĞLU ELLİK Z., YURDCU E., BOZDAYI A. M., İDİLMAN R.  
35. ULUSAL GASTROENTEROLOJİ HAFTASI, Antalya, Turkey, 21 November 2018
- XLVI. **Nonnasve Fbross Scores Are Not Useful for Predcton of Response to Treatment n Chronc Delta Hepatts**  
KESKİN O., YURDCU E., KALKAN Ç., ÇALIŞKAN KARTAL A., ELLİK Z., BOZDAYI A. M., İDİLMAN R., YURDAYDIN S. C.  
AASLD LIVER MEETING 2018, San-Francisco, Costa Rica, 9 - 13 November 2018
- XLVII. **Noninvasive Fibrosis Scores Are Not Useful for Prediction of Response to Treatment in Chronic Delta Hepatitis**  
Keskin O., Yurdcu E., Kalkan C., Kartal A., Ellik Z., Bozdayi M., İDİLMAN R., Yurdaydin C., Keskin O.  
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San-Francisco, Costa Rica, 9 - 13 November 2018, vol.68
- XLVIII. **Bir otoimmun poliglandüler sendrom tip 3 vakası**  
FIRAT S. N., TURHAN İYİDİR Ö., ANIL C., GÜLSOY KIRNAP N., MELEKOĞLU ELLİK Z.  
37. Türkiye Endokrinoloji ve Metabolizma Hastalıkları Kongresi, Antalya, Turkey, 6 - 10 May 2015
- XLIX. **Kronik Böbrek Yetmezliği Hastalarında Vasküler Kalsifikasyon ve Belirteçlerinin İlişkisi ve Bu İlişkiye Etki Eden Fatörler**  
BAL A. Z., TUTAL E., BAL U. A., ERKMEN UYAR M., MELEKOĞLU ELLİK Z., SEZER S.  
16.Ulusal Hipertansiyon ve Böbrek Hastalıkları Kongresi, Turkey, 21 - 25 May 2014

## Metrics

Publication: 79

Citation (WoS): 97

Citation (Scopus): 136

H-Index (WoS): 4

H-Index (Scopus): 5